Identification of genes that modify response to beta-d-N4-hydroxycytidine in mouse B cell lymphoma cell lines
A genome wide CRISPR-Cas9 screen was performed with two different mouse Eu-Myc transgenic B cell lymphoma cell lines. Cells were exposed to the antiviral drug beta-d-N4-hydroxycytidine (NHC/EIDD-1931) and sgRNA abundance monitored over four rounds of selection.